Medicus Pharma Ltd. (MDCX)
| Market Cap | 30.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 11.73M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,941 |
| Open | 2.800 |
| Previous Close | 2.590 |
| Day's Range | 2.500 - 2.800 |
| 52-Week Range | 1.800 - 3.100 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About MDCX
Medicus Pharma Ltd., a biotech/life sciences company, focuses on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. It is developing SkinJect with an indication for basal cell carcinoma. The company is headquartered in Toronto, Canada. [Read more]
News
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D Program Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D Program
Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States
Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 15, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the closing of its previously ann...
Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States
Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the pricing of its initial public...